Optimization of combination chemotherapy based on the calculation of network entropy for protein-protein interactions in breast cancer cell lines

EPJ Nonlinear Biomedical Physics

Table 2 The panel of cytotoxic drugs classified according to their therapeutic targets, primary effector pathways, or signaling pathway; and the sensitivity for each malignant cell lines

Drugs group	NuclSynt^a	Metab^b	DNA^c	Various^d	Average
Targets	I^e	II^f	III^g	IV^h
Lⁱ
MCF-7	4.72	NA	5.07	6.10	5.30
T-47D	3.01	4.46	5.19	5.39	4.51
ZR-75-1	5.16	4.16	5.99	5.65	5.24
BT-474	3.12	3.98	4.76	5.89	4.44
Correl.^j	0.500^j	0.433	0.961	−0.623	0.401
TN^k
BT-20	3.48	4.69	4.93	5.50	4.65
MDA-MB-231	3.44	4.13	5.71	5.40	4.67
MDA-MB-468	4.31	4.03	5.59	6.04	4.99
Correl.	−0.845	0.926	−0.785	−0.783	−0.891
Tot. correl.^l	0.197	0.633	0.486	−0.683	0.126

^aNuclSynt: DNA synthesis
^bMetab: antimetabolites
^cDNA: alter DNA structure
^dVarious: diverse spectrum of biological activities
^eI: TYMS, DNA, RNA, DHFR, GART
^fII: FDPS
^gIII: DNA cross-linker, TOP1, TOP2A, TOP2BA, TOP2AB, pyrimidine anti-metabolite
^hIV: PSMD2, PSMB1, PSMB5, PSMB2, PSMD1, IKBKB, SRC, MDM2, FLT3, NTRK1
ⁱLuminal: Luminal A and B
^jCorrel: Correlation of drug 50 with entropy per node (see Table 1)
^kTN: Triple-negative
^lTot. correl: correlation for L and TN together